Utomilumab is under clinical development by Pfizer and currently in Phase III for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase III drugs for Diffuse Large B-Cell Lymphoma have a 49% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Utomilumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Utomilumab overview

Utomilumab (PF-05082566) is under development for the treatment of relapsed or refractory diffuse large B-cell lymphoma, mantle cell lymphoma, ovarian cancer, colorectal cancer, follicular lymphoma, breast cancer, metastatic breast cancer and triple negative breast cancer. The drug candidate is a new molecular entity and is administered by intravenous route. It acts by targeting 4-1BB.

It was also under development for the treatment of squamous non-small cell lung cancer, head and neck cancer squamous cell carcinoma, squamous cell carcinoma of the uterine cervix, pancreatic cancer, gastric cancer, urothelial bladder cancer, metastatic hepatocellular carcinoma, sarcoma, renal cell carcinoma, relapsed or refractory acute myeloid leukemia (AML), thymoma (Thymic Epithelial Tumor), follicular lymphoma and anaplastic thyroid cancer, hematological tumor and solid tumor.

Pfizer overview

Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.

For a complete picture of Utomilumab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.